{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:34:15Z","timestamp":1787578455908,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    This Clinical Practice Update provides revised guidance related to an update to the requirements related to the elimination of the DATA-Waiver program. This document is a focused update of related content in Committee Opinion No. 711,\n                    <jats:italic toggle=\"yes\">Opioid Use and Opioid Use Disorder in Pregnancy<\/jats:italic>\n                    (Obstet Gynecol 2017;130:e81\u201394).\n                  <\/jats:p>","DOI":"10.1097\/aog.0000000000006066","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T21:00:34Z","timestamp":1757019634000},"page":"e105-e108","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["ACOG Clinical Practice Update: Elimination of the DATA-Waiver Program"],"prefix":"10.1097","volume":"146","author":[{"name":"ACOG Committee on Clinical Consensus\u2014Obstetrics","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"R2-20260824","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2023.4523","article-title":"Pregnancy and postpartum drug overdose deaths in the US before and during the COVID-19 pandemic","volume":"81","author":"Han","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"R3-20260824","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017 [published erratum appears in JAMA 2021;325:2316]","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"R4-20260824","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s10995-023-03614-7","article-title":"Opioid use disorder and overdose in the first year postpartum: a rapid scoping review and implications for future research","volume":"27","author":"Frankeberger","year":"2023","journal-title":"Matern Child Health J"},{"key":"R6-20260824","doi-asserted-by":"crossref","first-page":"103644","DOI":"10.1016\/j.ijoa.2023.103644","article-title":"Persistent opioid use after cesarean delivery in the United States of America: a systematic review","volume":"54","author":"Landau","year":"2023","journal-title":"Int J Obstet Anesth"},{"key":"R7-20260824","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","article-title":"Buprenorphine versus methadone for opioid use disorder in pregnancy","volume":"387","author":"Suarez","year":"2022","journal-title":"N Engl J Med"},{"key":"R8-20260824","doi-asserted-by":"crossref","first-page":"112632","DOI":"10.1016\/j.drugalcdep.2025.112632","article-title":"Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: a systematic review and meta-analysis","volume":"271","author":"de Lima","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"R9-20260824","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6928a1","article-title":"Vital signs: prescription opioid pain reliever use during pregnancy\u201434 U.S. jurisdictions, 2019","volume":"69","author":"Ko","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R12-20260824","doi-asserted-by":"crossref","first-page":"e2232314","DOI":"10.1001\/jamanetworkopen.2022.32314","article-title":"Racial and ethnic disparities in drug overdose deaths in the US during the COVID-19 pandemic","volume":"5","author":"Han","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R13-20260824","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1007\/s11606-023-08306-0","article-title":"Racial and ethnic inequities in buprenorphine and methadone utilization among reproductive-age women with opioid use disorder: an analysis of multi-state Medicaid claims in the USA","volume":"38","author":"Xu","year":"2023","journal-title":"J Gen Intern Med"},{"key":"R16-20260824","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/AOG.0000000000004517","article-title":"Pharmacologic stepwise multimodal approach for postpartum pain management. Clinical Consensus No. 1","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R21-20260824","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:09:12Z","timestamp":1787576952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006066","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}